DSGN Graph | Design Therapeutics, Inc.

DSGN Revenue Flow

Filed revenue amounts for 2026-01-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue (m); Research and development $16.39M; Operating expenses $22.18M; Net income -$20.16M.
2026-03-31: Revenue $0.00; Research and development $14.38M; Operating expenses $19.71M; Net income -$17.64M.
2025-12-31: Revenue $0.00*; Research and development $13.43M*; Operating expenses $18.17M*; Net income -$16.00M*.
2025-09-30: Revenue (m); Research and development $14.59M; Operating expenses $19.31M; Net income -$17.00M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	(m)	$16.39M	$22.18M	-$20.16M
2026-03-31	$0.00	$14.38M	$19.71M	-$17.64M
2025-12-31	$0.00*	$13.43M*	$18.17M*	-$16.00M*
2025-09-30	(m)	$14.59M	$19.31M	-$17.00M
2025-06-30	(m)	$15.74M	$21.57M	-$19.08M
2025-03-31	$0.00	$15.38M	$20.42M	-$17.71M
2024-09-30	(m)	$11.88M	$16.25M	-$13.04M
2024-06-30	(m)	$10.52M	$15.04M	-$11.79M
2024-03-31	(m)	$9.80M	$14.40M	-$11.11M
2023-09-30	(m)	$13.26M	$18.82M	-$15.79M
2023-06-30	(m)	$17.06M	$22.60M	-$19.94M
2023-03-31	(m)	$15.73M	$21.65M	-$19.29M
2022-09-30	(m)	$14.30M	$19.19M	-$17.70M
2022-06-30	(m)	$11.29M	$15.64M	-$15.00M
2022-03-31	(m)	$8.76M	$13.37M	-$13.27M
2021-09-30	(m)	$8.54M	$11.34M	-$11.32M
2021-06-30	(m)	$5.03M	$7.69M	-$7.64M
2021-03-31	(m)	$3.88M	$5.68M	-$5.51M
2020-09-30	$20.00K	$1.91M	$2.40M	-$2.32M
2020-06-30	$31.00K	$1.06M	$1.49M	-$1.44M
2020-03-31	$142.00K	$377.00K	$765.00K	-$663.00K

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$0.00	$30.77M	$41.88M	-$37.80M
2025-06-30	$0.00	$31.11M	$41.99M	-$36.80M
2024-06-30	(m)	$20.32M	$29.44M	-$22.90M
2023-06-30	(m)	$32.79M	$44.25M	-$39.23M
2022-06-30	(m)	$20.05M	$29.01M	-$28.26M
2021-06-30	(m)	$8.90M	$13.37M	-$13.15M
2020-06-30	$173.00K	$1.44M	$2.26M	-$2.10M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Net income
2025-09-30	$0.00	$45.70M	$61.30M	-$53.80M
2024-09-30	(m)	$32.19M	$45.69M	-$35.94M
2023-09-30	(m)	$46.05M	$63.07M	-$55.02M
2022-09-30	(m)	$34.36M	$48.20M	-$45.97M
2021-09-30	(m)	$17.44M	$24.70M	-$24.47M
2020-09-30	$193.00K	$3.35M	$4.66M	-$4.42M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$0.00	$59.13M	$79.47M	$0.00	-$69.79M
2024-12-31	$0.00	$44.35M	$62.38M	$0.00	-$49.59M
2023-12-31	(m)	$57.06M	$78.19M	(m)	-$66.86M
2022-12-31	(m)	$48.61M	$67.59M	(m)	-$63.31M
2021-12-31	(m)	$24.78M	$35.83M	(m)	-$35.53M
2020-12-31	$226.00K	$6.06M	$8.56M	(m)	-$8.28M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Wave Life Sciences, Inc. (WVE)		$0.780B	-5.56
Faeth Therapeutics, Inc. (FTH)	United States	$0.750B
Olema Pharmaceuticals, Inc. (OLMA)	United States	$0.790B	-5.35
Aclaris Therapeutics, Inc. (ACRS)	United States	$0.792B	-9.78
COLLEGIUM PHARMACEUTICAL, INC (COLL)	United States	$0.737B	24.57
GERON CORP (GERN)	United States	$0.803B	-12.14
GYRE THERAPEUTICS, INC. (GYRE)	United States	$0.818B	-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)	United States	$0.823B	-17.48
Verastem, Inc. (VSTM)	United States	$0.706B	-1.71
Nuvectis Pharma, Inc. (NVCT)	United States	$0.705B	-17.53